![Mark Throsby](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mark Throsby
Directeur Général chez Alethiomics Ltd.
Provenance du réseau au premier degré de Mark Throsby
Entité | Type d'entité | Industrie | |
---|---|---|---|
35
| Public Company | Biotechnology | 35 |
Crucell NV
![]() Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands.
23
| Extinct | Pharmaceuticals: Major | 23 |
Ona Therapeutics SL
![]() Ona Therapeutics SL Pharmaceuticals: MajorHealth Technology Ona Therapeutics SL is a biotech company based in Barcelona, Spain that specializes in discovering and developing therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. The Spanish company's focus is on developing novel therapies against advanced cancer. The company was founded in 2019 by Salvador Aznar Benitah and Valerie Liesbeth Brigitte Vanhooren, with Valerie Liesbeth Brigitte Vanhooren serving as CEO since incorporation.
9
| Holding Company | Pharmaceuticals: Major | 9 |
Alethiomics Ltd.
![]() Alethiomics Ltd. Miscellaneous Commercial ServicesCommercial Services Alethiomics Ltd. operates as a British biotechnology company. The company is based in Cambridge, UK. The company was founded in 2021 by Adam Joseph Mead, Bethan Psaila. The CEO is Mark Throsby.
5
| Holding Company | Miscellaneous Commercial Services | 5 |
Gadeta BV
![]() Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands.
4
| Subsidiary | Medical Specialties | 4 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Mark Throsby via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
Genentech, Inc.
![]() Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
ASTRAZENECA PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Private Equity Investor | |
NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Genzyme Corp.
![]() Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Nyenrode Business Universiteit | College/University | Director/Board Member Masters Business Admin | |
KALA BIO, INC. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
Nimbus Therapeutics LLC
![]() Nimbus Therapeutics LLC BiotechnologyHealth Technology Nimbus Therapeutics LLC provides drug discovery research services. It is a computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinical development. The company was founded by Bruce Lee Booth in 2009 and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Director/Board Member | |
AURA BIOSCIENCES, INC. | Biotechnology | Director/Board Member Director/Board Member | |
McKinsey & Co., Inc.
![]() McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
GSK Equity Investments Ltd.
![]() GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Investment Managers | Corporate Officer/Principal President | |
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Nederlandse Organisatie voor Toegepast-Natuurwetenschappelijk
![]() Nederlandse Organisatie voor Toegepast-Natuurwetenschappelijk Miscellaneous Commercial ServicesCommercial Services Nederlandse Organisatie voor Toegepast-Natuurwetenschappelijk provides scientific services. It includes research and consultancy for government, businesses and organizations. The company was founded in 1932 and is headquartered in Delft, Netherlands. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Massachusetts Institute of Technology | College/University | Undergraduate Degree Undergraduate Degree | |
INSEAD | College/University | Masters Business Admin Masters Business Admin | |
University of Amsterdam | College/University | Graduate Degree Corporate Officer/Principal Doctorate Degree Doctorate Degree | |
Janssen Vaccines & Prevention BV
![]() Janssen Vaccines & Prevention BV Pharmaceuticals: MajorHealth Technology Janssen Vaccines & Prevention BV manufactures and supplies biopharmaceutical products. The company was founded in 2000 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Chairman Chief Operating Officer Corporate Officer/Principal Corporate Officer/Principal | |
Erasmus University Rotterdam | College/University | Graduate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
University of Leiden | College/University | Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
University of Utrecht | College/University | Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree Graduate Degree Graduate Degree Doctorate Degree Doctorate Degree | |
Vrije Universiteit Amsterdam | College/University | Corporate Officer/Principal Graduate Degree | |
Polpharma Biologics Utrecht BV
![]() Polpharma Biologics Utrecht BV Miscellaneous Commercial ServicesCommercial Services Polpharma Biologics Utrecht BV operates as a biopharmaceutical research and development company. It specializes in the development of monoclonal antibodies generation, cell line, upstream process, downstream process, analytical, and bioassay development services. The company is headquartered in Utrecht, the Netherlands. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
Radboud University Nijmegen | College/University | Doctorate Degree Doctorate Degree | |
Humboldt-Universität zu Berlin | College/University | Doctorate Degree Doctorate Degree | |
AVANTIUM N.V. | Industrial Machinery | Director/Board Member Director/Board Member | |
ProFibrix BV
![]() ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Biotechnology | Director/Board Member Chairman Chief Tech/Sci/R&D Officer | |
Sanifit Therapeutics SA
![]() Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Biotechnology | Director/Board Member Chairman Director/Board Member | |
ARGENX SE | Pharmaceuticals: Other | Director/Board Member Director/Board Member | |
Batavia Biosciences BV
![]() Batavia Biosciences BV Pharmaceuticals: MajorHealth Technology Batavia Biosciences BV provides biopharmaceutical process development services. It offers biopharmaceutical materials research and pre-clinical study services for biopharmaceutical clients. The firm services cover candidate selection, production of research materials, upstream and downstream process development, assay development, product characterization and clinical manufacturing and release. The company was founded in 2010 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Chief Executive Officer Founder | |
DCPrime BV
![]() DCPrime BV Pharmaceuticals: MajorHealth Technology DCPrime BV engages in the provision of therapeutic vaccines for the treatment of cancer. It develops whole-cell-based vaccine addressing blood cancers with a high risk of relapse. The company was founded by Ada M. Kruisbeek and Rik J. Scheper in March 2005 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Chief Executive Officer Chief Executive Officer Director/Board Member | |
Pharmatching GmbH | Chief Executive Officer Chief Executive Officer | ||
iTeos Therapeutics SA
![]() iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Pharmaceuticals: Major | Director/Board Member Founder | |
Rainier Therapeutics, Inc.
![]() Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Biotechnology | Director/Board Member Director/Board Member | |
Anokion SA
![]() Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
Mimetas BV
![]() Mimetas BV BiotechnologyHealth Technology Mimetas BV develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models. It develops microfluidics-based culture plates that enable culturing and screening of a range of 3D organ and tissue models. The firm offers OrganoPlates microfluidics-based culture plates that serve as early stage screening models predicting toxic side effects and drug efficacy. The company was founded by Paul Vulto and Jos Joore in 2013 and is headquartered in Leiden, the Netherlands. | Biotechnology | Chairman Director/Board Member | |
Gist-Brocades NV | Corporate Officer/Principal Corporate Officer/Principal | ||
Kanyos Bio, Inc.
![]() Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Oxford Science Enterprises PLC
![]() Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | Investment Managers | Private Equity Investor Private Equity Investor | |
eTheRNA immunotherapies NV
![]() eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | Biotechnology | Chairman Director/Board Member Director/Board Member | |
Nimbus Apollo, Inc.
![]() Nimbus Apollo, Inc. Pharmaceuticals: MajorHealth Technology Nimbus Apollo, Inc. provides drug discovery research services. The company is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Oculis SA
![]() Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
KYMERA THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Hubrecht Organoid Technology Foundation | Director/Board Member Chairman Chief Executive Officer | ||
Q32 Bio, Inc.
![]() Q32 Bio, Inc. BiotechnologyHealth Technology Q32 Bio Operations, Inc. develops immunomodulatory therapies with protein based molecules using a platform. The company was founded by Shelia Violette and is headquartered in Cambridge, MA. | Biotechnology | Chairman Director/Board Member | |
Leyden Laboratories B.V.
![]() Leyden Laboratories B.V. Miscellaneous Commercial ServicesCommercial Services Leyden Laboratories B.V. is a biotechnology company based in Amsterdam, Netherlands. Leyden Labs aims to protect humanity from known and future viruses by targeting commonalities of viral families. The Dutch company has developed a portfolio of accessible intranasal product candidates that may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The company's energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. Leyden Labs is backed with $200m by blue-chip investors Casdin Capital, GV (formerly Google Ventures), F-Prime Capital, Byers Capital/Brook Byers, SoftBank Investment Advisers, Invus, and Bluebird Ventures. The company was founded in June 2020 by Koenraad Wiedhaup, Jaap Goudsmit, Domenico Valerio, and Ronald H. P. Brus, with Koenraad Wiedhaup serving as the CEO since incorporation. | Miscellaneous Commercial Services | Founder Founder |
Statistiques
Internationale
Pays-Bas | 23 |
Etats-Unis | 15 |
Royaume-Uni | 4 |
Suisse | 4 |
Allemagne | 3 |
Sectorielle
Health Technology | 25 |
Consumer Services | 10 |
Commercial Services | 8 |
Finance | 4 |
Health Services | 3 |
Opérationnelle
Director/Board Member | 350 |
Corporate Officer/Principal | 145 |
Chairman | 96 |
Independent Dir/Board Member | 83 |
Chief Executive Officer | 63 |
Relations les plus connectées
Insiders | |
---|---|
Jack Nielsen | 38 |
Elaine Jones | 37 |
Russell Greig | 31 |
Florent Gros | 28 |
Lionel Carnot | 27 |
Mark Iwicki | 26 |
Cees de Jong | 23 |
John Paul de Koning | 21 |
Stephen Brown Davis | 21 |
José Antonio Mesa Cejudo | 20 |
Pamela Klein | 19 |
Mark de Boer | 19 |
Anand Mehra | 18 |
Björn Magnus Sjöstrand | 17 |
Bill Lundberg | 17 |
- Bourse
- Insiders
- Mark Throsby
- Connexions Sociétés